Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy

Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, Untch M, Salat C, Huober J, Klare P, Schmutzler R, Couch FJ, Lederer B, Gerber B, Zahm DM, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Fasching P (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Book Volume: 145

Pages Range: 44-52

DOI: 10.1016/j.ejca.2020.12.007

Abstract

Background: BRCA1 and BRCA2 play a central role in DNA repair. Therefore, patients harbouring germline (g) BRCA1/2 mutations (m) treated with chemotherapy might be at higher risk of haematological toxicities. Methods: Patients from German Breast Group (GBG) and Arbeitsgemeinschaft Gynäkologische Onkologie-breast group studies with early triple-negative breast cancer (TNBC) and known gBRCA1/2m status treated with anthracycline-taxane-based neoadjuvant chemotherapy were analysed. Primary objective was the rate of neutropenia grade (G)III–IV in cycle 1 (C1). Secondary objectives included effects on overall and other haematological toxicities GIII-IV in C1, cumulative haematological toxicity across all cycles, relative total dose intensity, and granulocyte-colony stimulating factor prophylaxis. Haematological toxicities under taxanes, carboplatin, and cyclophosphamide were explored. Results: Two hundred nine of 1171 (17.8%) evaluated patients had gBRCA1/2m. In C1, 37.4% gBRCA1/2m versus 35.7% wild-type patients had neutropenia GIII-IV (P = 0.683). For C1, gBRCA1/2m predicted neither for neutropenia GIII-IV (odds ratio [OR]: 1.26, 95% confidence intervals [CI]: 0.87–1.82, P = 0.226) nor for other haematological toxicities GIII-IV (OR: 0.91, 95% CI: 0.64–1.31, P = 0.625) in multivariable regression models. Analyses of cumulative toxicities across all cycles yielded similar results except thrombocytopaenia GIII-IV, which was increased in gBRCA1m patients. In patients treated with taxanes, the rate of haematological toxicities GIII-IV was higher in gBRCA1/2m compared with wild-type (59.5% versus 43.1%; p < 0.001). No difference was seen under cyclophosphamide or platinum-containing chemotherapies. Conclusions: gBRCA1/2m was not associated with higher risk of overall severe haematological toxicities in the first cycle or cumulatively across all cycles under standard chemotherapy for TNBC. Under taxane, patients with gBRCA1/2m might have a higher risk of haematological toxicities GIII-IV, requiring further research.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Ulm Germany (DE) Klinikum Landshut Germany (DE) Mayo Clinic United States (USA) (US) Sana Kliniken AG Germany (DE) GBG Forschungs GmbH (German Breast Group) Germany (DE) Centrum für Hämatologie und Onkologie Bethanien Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Universitätsklinikum Köln Germany (DE) DIAKOVERE gGmbH (Diakonische Dienste Hannover (DDH)) Germany (DE) Klinikum Südstadt Rostock Germany (DE) Medionko-Institut GbR Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) SRH Wald-Klinikum Gera Germany (DE) HELIOS Kliniken Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE)

How to cite

APA:

Furlanetto, J., Möbus, V., Schneeweiss, A., Rhiem, K., Tesch, H., Blohmer, J.U.,... Fasching, P. (2021). Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer, 145, 44-52. https://doi.org/10.1016/j.ejca.2020.12.007

MLA:

Furlanetto, Jenny, et al. "Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy." European Journal of Cancer 145 (2021): 44-52.

BibTeX: Download